

# Fabio Gelsomino

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1427260/fabio-gelsomino-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

1,716

citations

15

h-index

41

g-index

70

ext. papers

2,326

ext. citations

4.2

avg. IF

4.41

L-index

#	Paper	IF	Citations
62	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 773-779	2.2	938
61	The evolving role of microsatellite instability in colorectal cancer: A review. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 51, 19-26	14.4	133
60	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 33210-9	3.3	98
59	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	50
58	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , <b>2018</b> , 60, 490-498	4	41
57	Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. <i>Neuroendocrinology</i> , <b>2016</b> , 103, 806-14	5.6	38
56	Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3954-3961	12.9	36
55	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , <b>2020</b> , 271, 527-533	7.8	27
54	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , <b>2020</b> , 40, 704-711	7.9	25
53	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 635-635	2.2	22
52	The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 441-5	3.9	20
51	Lenvatinib as a therapy for unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 1069-1076	3.5	19
50	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 554-554	2.2	18
49	Erratum to Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanoma <i>Disease Markers</i> , <b>2014</b> , 2014, 1-1	3.2	17
48	Magnetic resonance imaging performed before and after preoperative chemoradiotherapy in rectal cancer: predictive factors of recurrence and prognostic significance of MR-detected extramural venous invasion. <i>Abdominal Radiology</i> , <b>2020</b> , 45, 2941-2949	3	16
47	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 315-321	8.7	15
46	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , <b>2018</b> , 18, 198-203	3.8	14

45	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	14
44	Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters. <i>Human Pathology</i> , <b>2018</b> , 78, 115-124	3.7	13
43	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. <i>European Journal of Cancer</i> , <b>2019</b> , 117, 84-90	7.5	13
42	Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 4357-4369	3.6	10
41	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , <b>2020</b> , 25, 259-265	5.7	9
40	The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9
39	Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas. <i>Disease Markers</i> , <b>2014</b> , 2014, 671283	3.2	9
38	Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. <i>BMJ Open</i> , <b>2020</b> , 10, e034393	3	8
37	The perception of health-related quality of life in colon cancer patients during chemotherapy: differences between men and women. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 423-9	3.7	7
36	Chemotherapy with capecitabine plus temozolomide (CAP-TEM) in patients with advanced neuroendocrine neoplasms (NENS): an Italian multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15174-e15174	2.2	7
35	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, 410-415.e1	3.8	6
34	The treatment of rectal cancer with synchronous liver metastases: A matter of strategy. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 139, 91-95	7	6
33	The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	6
32	mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
31	Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. <i>Scientific Reports</i> , <b>2017</b> , 7, 10426	4.9	5
30	BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2016</b> , 24, 30-4	1.9	5
29	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
28	Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 5261-5268	4.4	5

27	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 1513-1527	3	4
26	Abstract 2603: Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab + ipilimumab in CheckMate-142 <b>2018</b> ,		4
25	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3590-3590	2.2	4
24	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	4
23	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 71-80	1.3	4
22	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. <i>Endocrine</i> , <b>2021</b> , 72, 268-278	4	4
21	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 712053	5.3	3
20	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
19	To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 132, 154-160	7	3
18	Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. <i>Gastrointestinal Tumors</i> , <b>2018</b> , 5, 14-20	1.3	2
17	Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920937427	5.4	2
16	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1
15	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 82-90.e9	3.8	1
14	Comment on Chun et al, "A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases". <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, e262-e263	3.8	1
13	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , <b>2021</b> , 30, 2455	3.9	1
12	Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience. <i>Endocrine</i> , <b>2021</b> , 74, 707-713	4	1
11	Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 27, 766-770	1.7	1
10	Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 322-322	2.2	1

9	The immune checkpoint CD73 (NT5E) in gastric adenocarcinoma (GAC): Biological characterization and clinical implications.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 235-235	2.2	1
8	Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> ,	4.2	1
7	Second-line chemotherapy in advanced biliary tract cancer: Who may benefit?. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 381-381	2.2	0
6	A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3607-3607	2.2	0
5	Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management.. <i>Current Oncology</i> , <b>2022</b> , 29, 1223-1236	2.8	0
4	Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection. <i>Acta Biomedica</i> , <b>2020</b> , 92, e2021061	3.2	
3	Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e15503-e15503	2.2	
2	Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 983-993	3.6	
1	Multicentre match-paired analysis of advanced biliary cancer long-term survivors: the BILONG study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2022</b> , 101955	2.4	